腎臓がんの診断と治療薬の世界市場レポート 2025年

腎臓がんの診断と治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.0％で56億8,000万米ドルに成長します。予測期間の成長は、バイオマーカー調査、ゲノムシークエンシングの進歩、遠隔医療と遠隔診察、精密医療の進歩、迅速診断技術に起因しています。予測期間の主な動向には、緩和ケアの統合、長期生存ケア、栄養とライフスタイルの介入、ラジオミクスの役割拡大、リキッドバイオプシーの採用などがあります。

腎臓がん罹患率の増加が予想され、腎臓がんの診断と治療薬市場拡大の原動力となります。腎臓がんは、正常な腎臓細胞の異常な変化により、制御不能な増殖と腎皮質腫瘍の形成を特徴とし、最適な疾患管理のために効果的な診断と治療が必要です。これらの要素には、早期発見、正確な診断、個別化医療、治療モニタリングなど、いくつかの利点があります。2023年3月の米国臨床腫瘍学会（ASCO）によると、米国では2023年に81,800人が腎臓がんと診断され、2020年には世界全体で431,288人が腎臓がんと診断されると推定されています。その結果、腎臓がんの有病率の増加が腎臓がんの診断と治療薬市場の成長を促進すると予想されます。

予想されるヘルスケア支出の増加は、今後の腎臓がんの診断と治療薬市場の成長を促進すると見られています。ヘルスケア支出には、特定の地域、国、組織内のヘルスケア部門に割り当てられる総財源が含まれます。腎臓がんの診断と治療薬への投資は、早期発見、効果的な治療、患者の転帰改善のために極めて重要です。この投資は、タイムリーな介入のための診断ニーズと、最適なケアのための治療要件に対応し、最終的に全体的な健康の向上と長期的な医療費の削減に貢献します。例えば、2022年3月、米国保健福祉省のメディケア＆メディケイドサービスセンターは、2021年から2030年の国民医療費（NHE）報告書を発表し、2021年から2030年までの国民医療費は年平均5.1％増加し、総支出は2030年までに約6兆8,000億米ドルに達すると予測しました。このように、ヘルスケア支出の増加が腎臓がんの診断と治療薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腎臓がんの診断と治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の腎臓がんの診断と治療薬市場：成長率分析
• 世界の腎臓がんの診断と治療薬市場の実績：規模と成長, 2019-2024
• 世界の腎臓がんの診断と治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界腎臓がんの診断と治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腎臓がんの診断と治療薬市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 明細胞腎細胞がん
• 乳頭状腎細胞がん
• クロモフォブ RCC
• 尿路上皮がんと移行上皮がん
• その他のがんの種類
• 世界の腎臓がんの診断と治療薬市場：コンポーネント別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• 診断
• 世界の腎臓がんの診断と治療薬市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生検
• CTスキャン
• 腎尿管鏡検査
• 静脈性腎盂造影検査
• 超音波
• 世界の腎臓がんの診断と治療薬市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 免疫療法
• 化学療法
• 世界の腎臓がんの診断と治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 製薬研究室
• ゲノミクス研究所
• 世界の腎臓がんの診断と治療薬市場、明細胞腎細胞がんのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ステージI
• ステージ II
• ステージIII
• ステージIV
• 世界の腎臓がんの診断と治療薬市場乳頭状腎細胞がんのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ1
• タイプ2
• 世界の腎臓がんの診断と治療薬市場、嫌色性腎細胞がんのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ローカライズ
• 先進型
• 世界の腎臓がんの診断と治療薬市場尿路上皮がんと移行上皮がんの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 筋肉を侵襲しない
• 筋肉侵襲性
• 転移性
• 世界の腎臓がんの診断と治療薬市場、その他のがんの種類のサブセグメンテーション、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 集合管がん
• 腎髄質がん
• その他の珍しいタイプ

第7章 地域別・国別分析

• 世界の腎臓がんの診断と治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腎臓がんの診断と治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎臓がんの診断と治療薬市場：競合情勢
• 腎臓がんの診断と治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A
• Bristol-Myers Squibb Pharmaceuticals Limited
• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Amgen Inc.
• Siemens Healthcare GmbH
• Laboratory Corporation of America Holdings
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Illumina Inc.
• PerkinElmer Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腎臓がんの診断と治療薬市場2029：新たな機会を提供する国
• 腎臓がんの診断と治療薬市場2029：新たな機会を提供するセグメント
• 腎臓がんの診断と治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Kidney cancer diagnostics and therapeutics encompass methods and treatments utilized for diagnosing and managing kidney cancer, specifically renal cell carcinoma. The primary objectives of these approaches are to detect the presence of kidney cancer, assess its stage and extent, and offer appropriate treatment options to effectively manage the disease.

The main types of kidney cancer include clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, transitional cell carcinoma, and others. Clear-cell renal cell carcinoma (RCC) is the predominant type, accounting for the majority of kidney cancer cases. RCC is further categorized into various subtypes based on the microscopic appearance of cancer cells. Kidney cancer diagnostics and therapeutics play a crucial role in managing clear cell renal cell carcinoma (RCC), the most prevalent subtype of kidney cancer. Treatment involves the use of components such as drugs and diagnostics, with diagnostics including biopsy, CT scan, nephro-ureteroscopy, intravenous pyelogram, and ultrasound. Therapies for kidney cancer include targeted therapy, immunotherapy, and chemotherapy. The main end-users of these diagnostics and therapeutics are hospitals, pharmaceutical labs, and genomic laboratories.

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides kidney cancer diagnostics and therapeutics market statistics, including kidney cancer diagnostics and therapeutics industry global market size, regional shares, competitors with a kidney cancer diagnostics and therapeutics market share, detailed kidney cancer diagnostics and therapeutics market segments, kidney cancer diagnostics and therapeutics market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. This kidney cancer diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $4.1 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, healthcare access improvements

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to biomarker research, genomic sequencing advances, telemedicine and remote consultations, precision medicine advancements, rapid diagnostic technologies. Major trends in the forecast period include palliative care integration, long-term survivorship care, nutrition and lifestyle intervention, expanded role of radiomics, liquid biopsies adoption.

The anticipated rise in kidney cancer prevalence is poised to be a driving force behind the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer, characterized by abnormal changes in normal kidney cells leading to uncontrolled growth and the formation of renal cortical tumors, necessitates effective diagnostics and therapeutics for optimal disease management. These components offer several advantages, including early detection, precise diagnosis, personalized medicine, and treatment monitoring. As per the American Society of Clinical Oncology (ASCO) in March 2023, it is estimated that 81,800 individuals in the United States will be diagnosed with kidney cancer in 2023, with a global impact of 431,288 cases in 2020. Consequently, the increasing prevalence of kidney cancer is expected to foster the growth of the kidney cancer diagnostics and therapeutics market.

The anticipated increase in healthcare spending is expected to drive the growth of the kidney cancer diagnostics and therapeutics market in the future. Healthcare spending encompasses the total financial resources allocated to the healthcare sector within a specific region, country, or organization. Investing in kidney cancer diagnostics and therapeutics is crucial for early detection, effective treatment, and improved patient outcomes. This investment addresses the diagnostic needs for timely intervention and the therapeutic requirements for optimal care, ultimately contributing to better overall health and reducing long-term healthcare costs. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, published the 2021-2030 National Health Expenditure (NHE) report, predicting an average annual increase in national health spending of 5.1% from 2021 to 2030, with total spending expected to reach approximately $6.8 trillion by 2030. Thus, the rise in healthcare spending is driving the growth of the kidney cancer diagnostics and therapeutics market.

Major companies in the kidney cancer diagnostics and therapeutics market are concentrating on the development of advanced treatments for renal cell carcinoma (RCC) to enhance patient outcomes and offer innovative treatment options tailored to the unique needs of individuals diagnosed with this complex disease. Research focused on renal cell carcinoma (RCC) is vital for the advancement of kidney cancer diagnostics and therapeutics, as it fosters the creation of new diagnostic techniques and targeted therapies that facilitate early diagnosis and personalized treatment plans for patients. For example, in December 2023, Merck, a US-based pharmaceutical company, introduced welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) following previous treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This groundbreaking therapeutic class offers notable advantages, including enhanced progression-free survival and higher response rates compared to everolimus. The approval of WELIREG signifies a significant advancement in the kidney cancer diagnostics and therapeutics market, providing renewed hope for patients facing disease progression.

Major companies in the kidney cancer diagnostics and therapeutics market are focusing on adapting clinical trial collaborations to enhance research capabilities, speed up the development of innovative treatments, and improve patient access to cutting-edge therapies through shared expertise and resources. These collaborations are crucial for advancing kidney cancer diagnostics and therapeutics, as they combine expertise, resources, and data, thereby accelerating the creation of novel treatments and diagnostic tools, and enhancing patient outcomes through more effective therapies. For instance, in December 2023, Exelixis, Inc., a US-based company, announced a clinical trial collaboration with Arcus Biosciences Inc., also based in the US, to evaluate Zanzalintinib in combination with AB521 for patients with advanced renal cell carcinoma (RCC). This clinical trial, designated as STELLAR-009, is a Phase 1b/2 study aimed at assessing the safety, tolerability, and preliminary efficacy of Zanzalintinib when used alongside AB521. The trial will also evaluate the pharmacokinetics (PK) of these drugs in patients with advanced clear cell renal cell carcinoma (ccRCC) and other solid tumors.

In May 2023, Telix Pharmaceuticals Limited, an Australia-based biotechnology research firm, acquired QSAM Biosciences, Inc. for an undisclosed amount. This acquisition is intended to strengthen Telix's portfolio in the development of targeted radiopharmaceuticals, especially for cancer treatment. By incorporating QSAM's expertise and technologies, Telix aims to accelerate the advancement of its innovative therapies and expand its market presence in the precision medicine sector. QSAM Biosciences Inc. is a biotechnology research company based in the US.

Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kidney cancer diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Cancer Diagnostics And Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney cancer diagnostics and therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney cancer diagnostics and therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer diagnostics and therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Clear Cell RCC; Papillary RCC; Chromophobe RCC; Urothelial Carcinoma And Transitional Cell Carcinoma; Other Cancer Types
• 2) By Component: Drugs; Diagnostics
• 3) By Diagnostics: Biopsy; CT Scan; Nephro-Ureteroscopy; Intravenous Pyelogram; Ultrasound
• 4) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy
• 5) By End-Users: Hospitals; Pharmaceutical Labs; Genomics Laboratories
• Subsegments:
• 1) By Clear Cell RCC: Stage I; Stage II; Stage III; Stage IV
• 2) By Papillary RCC: Type 1; Type 2
• 3) By Chromophobe RCC: Localized; Advanced
• 4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive; Muscle invasive; Metastatic
• 5) By Other Cancer Types: Collecting Duct Carcinoma; Renal Medullary Carcinoma; Other rare types
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kidney Cancer Diagnostics And Therapeutics Market Characteristics

3. Kidney Cancer Diagnostics And Therapeutics Market Trends And Strategies

4. Kidney Cancer Diagnostics And Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Kidney Cancer Diagnostics And Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Kidney Cancer Diagnostics And Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Kidney Cancer Diagnostics And Therapeutics Market Growth Rate Analysis
• 5.4. Global Kidney Cancer Diagnostics And Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Kidney Cancer Diagnostics And Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Kidney Cancer Diagnostics And Therapeutics Total Addressable Market (TAM)

6. Kidney Cancer Diagnostics And Therapeutics Market Segmentation

• 6.1. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clear Cell RCC
• Papillary RCC
• Chromophobe RCC
• Urothelial Carcinoma And Transitional Cell Carcinoma
• Other Cancer Types
• 6.2. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Diagnostics
• 6.3. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy
• CT Scan
• Nephro-Ureteroscopy
• Intravenous Pyelogram
• Ultrasound
• 6.4. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• 6.5. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmaceutical Labs
• Genomics Laboratories
• 6.6. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Clear Cell RCC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stage I
• Stage II
• Stage III
• Stage IV
• 6.7. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Papillary RCC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 2
• 6.8. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Chromophobe RCC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Localized
• Advanced
• 6.9. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Urothelial Carcinoma And Transitional Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-muscle invasive
• Muscle invasive
• Metastatic
• 6.10. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Other Cancer Types, BY Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Collecting Duct Carcinoma
• Renal Medullary Carcinoma
• Other rare types

7. Kidney Cancer Diagnostics And Therapeutics Market Regional And Country Analysis

• 7.1. Global Kidney Cancer Diagnostics And Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Kidney Cancer Diagnostics And Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market

• 8.1. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kidney Cancer Diagnostics And Therapeutics Market

• 9.1. China Kidney Cancer Diagnostics And Therapeutics Market Overview
• 9.2. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kidney Cancer Diagnostics And Therapeutics Market

• 10.1. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kidney Cancer Diagnostics And Therapeutics Market

• 11.1. Japan Kidney Cancer Diagnostics And Therapeutics Market Overview
• 11.2. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kidney Cancer Diagnostics And Therapeutics Market

• 12.1. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kidney Cancer Diagnostics And Therapeutics Market

• 13.1. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kidney Cancer Diagnostics And Therapeutics Market

• 14.1. South Korea Kidney Cancer Diagnostics And Therapeutics Market Overview
• 14.2. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kidney Cancer Diagnostics And Therapeutics Market

• 15.1. Western Europe Kidney Cancer Diagnostics And Therapeutics Market Overview
• 15.2. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kidney Cancer Diagnostics And Therapeutics Market

• 16.1. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kidney Cancer Diagnostics And Therapeutics Market

• 17.1. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kidney Cancer Diagnostics And Therapeutics Market

• 18.1. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kidney Cancer Diagnostics And Therapeutics Market

• 19.1. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kidney Cancer Diagnostics And Therapeutics Market

• 20.1. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market

• 21.1. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market Overview
• 21.2. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kidney Cancer Diagnostics And Therapeutics Market

• 22.1. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kidney Cancer Diagnostics And Therapeutics Market

• 23.1. North America Kidney Cancer Diagnostics And Therapeutics Market Overview
• 23.2. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kidney Cancer Diagnostics And Therapeutics Market

• 24.1. USA Kidney Cancer Diagnostics And Therapeutics Market Overview
• 24.2. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kidney Cancer Diagnostics And Therapeutics Market

• 25.1. Canada Kidney Cancer Diagnostics And Therapeutics Market Overview
• 25.2. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kidney Cancer Diagnostics And Therapeutics Market

• 26.1. South America Kidney Cancer Diagnostics And Therapeutics Market Overview
• 26.2. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kidney Cancer Diagnostics And Therapeutics Market

• 27.1. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kidney Cancer Diagnostics And Therapeutics Market

• 28.1. Middle East Kidney Cancer Diagnostics And Therapeutics Market Overview
• 28.2. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kidney Cancer Diagnostics And Therapeutics Market

• 29.1. Africa Kidney Cancer Diagnostics And Therapeutics Market Overview
• 29.2. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kidney Cancer Diagnostics And Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Kidney Cancer Diagnostics And Therapeutics Market Competitive Landscape
• 30.2. Kidney Cancer Diagnostics And Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Kidney Cancer Diagnostics And Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol-Myers Squibb Pharmaceuticals Limited
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. AstraZeneca PLC
• 31.5. Abbott Laboratories
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Co Ltd.
• 31.8. Amgen Inc.
• 31.9. Siemens Healthcare GmbH
• 31.10. Laboratory Corporation of America Holdings
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Astellas Pharma Inc.
• 31.13. Eisai Co. Ltd.
• 31.14. Illumina Inc.
• 31.15. PerkinElmer Inc.

32. Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kidney Cancer Diagnostics And Therapeutics Market

34. Recent Developments In The Kidney Cancer Diagnostics And Therapeutics Market

35. Kidney Cancer Diagnostics And Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Kidney Cancer Diagnostics And Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Kidney Cancer Diagnostics And Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Kidney Cancer Diagnostics And Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer